Question · asked by 1 review
BENZODIAZEPINES AS SOLE TREATMENT vs placebo: Unacceptability of treatment (drop-outs / leaving study early)
- Population
- patients with schizophrenia
- Intervention
- BENZODIAZEPINES AS SOLE TREATMENT
- Comparison
- placebo
- Outcome
- Unacceptability of treatment (drop-outs / leaving study early)
It is very uncertain whether BENZODIAZEPINES AS SOLE TREATMENT changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
BENZODIAZEPINES AS SOLE TREATMENT vs PLACEBO Leaving the study early due to any reason (overall acceptability of treatment) · people with schizophrenia It is very uncertain whether BENZODIAZEPINES AS SOLE TREATMENT changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO (very low certainty). Benzodiazepines for schizophrenia (2012) · Cochrane Headline outcomes only | RR 0.89 [0.57, 1.38] | 8 studies · 440 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Benzodiazepines for schizophrenia 2012 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.